New Immune-Boosting Innovation: Beyond the Vitamins and Minerals

Levagen® is a clinically studied form of palmitoylethanolamide (PEA).

Existing literature demonstrates PEA's ability to boost the immune system and provide symptomatic relief of flu symptoms. 

This is done via numerous pathways, such as the activation of PPAR-a and inhibiting mast cell deregulation. 

Learn more about PEA's immune-boosting mechanisms, make sure to download the Levagen+ Immune Health White Paper below.

Download Whitepaper »

Levagen+® is an innovative highly bioavailable form of palmitoylethanolamide (PEA).

Levagen® is also available in a cold water dispersible format, under Levagen+®. Levagen+® is powered by LipiSperse® technology, developed by award-winning Pharmako Biotechnologies, to increase functionality and bioavailability of PEA for food and beverage applications.

Levagen® is also self-affirmed GRAS, further substantiating its safety.

Clinical Research

Levagen®: Human clinical trial for management of mild to moderate osteoarthritis symptoms*

Study Results: The effectiveness and safety of Levagen® has been recently studied in a double-blinded, randomized, placebo-controlled study. The clinical trial studied 120 patients with 40 patients on placebo, 40 patients on Levagen® 300 mg a day and 40 patients on Levagen® 600 mg a day. Both the 600 mg and the 300 mg doses were found to be statistically significant compared to the placebo on the total WOMAC score, pain subdomain, stiffness subdomain and function subdomain.*

Levagen+®: Double-blind Bioavailability Study

Study Results: A parallel, double-blind, bioavailability study was conducted with 28 healthy male and female volunteers over 18 years old to measure uptake of Levagen+® PEA over a 24-hour period. The objective of this trial was to determine whether the use of a lipid-based drug delivery system, LipiSperse®, can be successfully used to improve the bioavailability of Levagen®.

The Levagen+® formulation significantly increased plasma PEA concentration by approximately 1.8 times that of the standard PEA formulation*. The results indicate that by combining Levagen® with LipiSperse® delivery system, PEA absorption is more effective.*

1 Petrosino S, et al. The anti-inflammatory mediator palmitoylethanolamide enhances the levels of 2-arachidonoyl-glycerol and potentiates its actions at TRPV1 cation channels. BrJ Pharmacol. 2015

Clinical research

Levagen+ Recovery Study

  • A double-blind, randomised, placebo-controlled study to evaluate the effect of orally-dosed
    Levagen Plus on exercise recovery in healthy males.
  • 28 males (aged 18-35 years)
  • 72-hour treatment duration with 2 trial arms: Levagen+ 168mg and Placebo
  • 30 minutes after ingestion of product, participants were exercised to induce local leg muscle fatigue using a leg press (4 sets of 80% of 1RM). Participants consumed the supplement again post-workout and dosed once daily for three days thereafter.
  • Blood parameters, VAS pain score, thigh circumference, and questionnaires were taken immediately, 1, 2, 3, 24, 48, and 72-hours post-exercise.
  • Two hours post exercise fatigue the participant again completed 1 set of leg press reps at 70% of maximal until exhaustion to measure performance.


  • 168mg Levagen reduced lactate and muscle damage compared to placebo
  • Decreased lactate and lactate dehydrogenase, correlating to increased aerobic energy metabolism and decreased anaerobic energy metabolism. This may allow individuals to exercise at higher intensities for longer than those in the placebo group.
  • Reduced muscle damage in myoglobin, correlating to improved performance as individuals may be subject to higher exercise intensities for longer, allowing for an improved training response.

The results suggest that Levagen Plus may allow individuals to train for harder and longer than placebo. This may be due to its ability to reduce muscle damage and spare anaerobic energy metabolism, which increases lactate threshold.